AZ, Lilly join efforts to develop drugs for COVID-19AstraZeneca and Eli Lilly have joined the ranks of drugmakers around the world trying to repurpose existing drugs Share XAZ, Lilly join efforts to develop drugs for COVID-19https://pharmaphorum.com/news/az-lilly-join-efforts-to-develop-drugs-for-covid-19/
ASH19: AZ’s Calquence throws gauntlet down to ImbruvicaAstraZeneca’s resurgent cancer division could have another winner on its hands. Stellar data with newly-approved BTK inhibitor Calquence Share XASH19: AZ’s Calquence throws gauntlet down to Imbruvicahttps://pharmaphorum.com/news/ash19-azs-calquence-throws-gauntlet-down-to-imbruvica/
FDA nod for AZ’s Calquence sets up new Imbruvica showdownAbbVie and Johnson & Johnson are facing a challenge to their blockbuster chronic lymphocytic leukaemia drug Imbruvica from Share XFDA nod for AZ’s Calquence sets up new Imbruvica showdownhttps://pharmaphorum.com/news/fda-nod-for-azs-calquence-sets-up-new-imbruvica-showdown/
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmentAstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this Share XAZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmenthttps://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/
AstraZeneca ends another Calquence trial earlyFor the second time in the space of a month AstraZeneca has stopped a trial of its chronic Share XAstraZeneca ends another Calquence trial earlyhttps://pharmaphorum.com/news/astrazeneca-ends-another-calquence-trial-early/
AstraZeneca ends leukaemia trial early after promising resultsAstraZeneca has said that it will stop a Phase III trial of its chronic lymphocytic leukaemia drug Calquence Share XAstraZeneca ends leukaemia trial early after promising resultshttps://pharmaphorum.com/news/astrazeneca-ends-leukaemia-trial-early-after-promising-results/
